The in vitro diagnostics (IVD) sector stands as a cornerstone of modern healthcare, empowering clinicians with the tools to detect diseases, monitor health conditions, and guide precise treatment decisions.
As healthcare evolves, the IVD market is poised for transformative growth. With the rising prevalence of chronic conditions such as diabetes and cardiovascular diseases, as well as ongoing threats from infectious diseases like COVID-19 and emerging variants, the demand for innovative diagnostic solutions has never been greater.
In Vitro Diagnostics Business Outlook is a bimonthly publication, delivering six issues annually, each dedicated to a different segment of the IVD industry. It provides exclusive insights and data, including:
- Market Data and Forecasts: Detailed growth rates, market size, and market share to identify new opportunities.
- Comprehensive Market View: Coverage of test categories and company profiles.
- M&A Activities: Updates on mergers, acquisitions, partnerships, and collaborations.
- Industry & Region Watch: Tailored strategies based on regional and industry-specific trends.
- News Analysis: In-depth reporting on significant news and events, including exclusive information not readily available elsewhere.
- ABOUT KALORAMA INFORMATION
- MARKET ANALYSIS: BLOOD GROUPING/TYPING TESTING
- OVERVIEW OF BLOOD GROUPING/TYPING TESTING
- Molecular Methods in Blood Typing
- Discovery of a New Blood Group System
- MARKET OUTLOOK: BLOOD GROUPING AND TYPING
- OVERVIEW OF BLOOD GROUPING AND TYPING
- Regional Market
- Figure: Blood Grouping/Typing Market, Estimated Revenues, by Global Region, 2019-2029 [Asia Pacific, Europe, North America, Rest of World]
- Company Briefs
- Bio-Rad
- Grifols
- QuidelOrtho
- Figure: Global Blood Grouping/Typing Market Share, by Vendor, 2024 (%) [Bio-Rad, Grifols, QuidelOrtho, Others]
- Werfen/Immucor
- AliveRx/Quotient
- EXECUTIVE NEWS BRIEFING
- BRIEFS
- Craif Raises $22 Million in Series C Funding
- Deepull Closes Series C Financing Round
- Upfront Diagnostics Raises $4.3 million in Funding Round
- Cizzle Biotechnology Raises £150,000 in Additional Funding
- Hedera Dx Lands €15 Million in Funding
- 32 Biosciences Secures $6 Million in Funding
- FINANCIAL HIGHLIGHTS: BIOMÉRIEUX & TRINITY BIOTECH
- bioMérieux Reports Full-Year 2024 Sales of €3,980 Million, Representing 10.3% Organic Growth and Exceeding Expectations
- Figure: Trinity Biotech Sales, by Business Segment, FY 2023 and FY 2024 ($ thousands) [Clinical Laboratory, Point-of-Care]
- DIAGNOSTIC MARKET MERGERS, ACQUISITIONS, AND PARTNERSHIP DEALS
- PARTNERSHIPS AND COLLABORATIONS
- RECENT MERGERS AND ACQUISITIONS
- Table: Recent Diagnostic Market Mergers, Acquisitions, and Partnership Deals, December 2024-June 2025
- INDUSTRY WATCH
- INDUSTRY WATCH COVID-19/FLU UPDATE
- REGION WATCH
- CHINA
- Figure: China Total Health Expenditures, $B and Total Population, 2010-2023
- Figure: China IVD Market Distribution of Sales, by IVD Segment, 2024 (%)
- BROAD-BASED COMPANY ANNOUNCEMENTS
- COMPANY ANNOUNCEMENTS
- Guardant Health Launches New Hereditary Cancer Test
- EDX Medical Launches Test for Early Testicular Cancer Detection
- Lumipulse G pTau 217 β-Amyloid 1-42 Plasma Ratio Receives FDA Clearance
- Boditech and SphingoTec Launch AFIAS Sphingotest penKid Assay
- Roche Plans Investment of $550 Million for Indianapolis Diagnostic Site
- Roche Receives FDA Breakthrough Device Designation
- DiaSorin Captures FDA Clearance for Multiplex Molecular Panel
- Nordic Bioscience Launches nordicEndotrophin Assay
- genedrive Certification of Rapid CYP2C19 ID Kit
- Predicta Biosciences Launches GenoPredicta Marrow and GenoPredicta Blood
- Baebies Received FDA Breakthrough Device Designation
- New Day Diagnostics Launches ColoHealth
- Randox Received FDA Go-Ahead for ConcizuTrace ELISA
- LifeLabs Introduces Three Blood-Based Alzheimer’s Disease Tests
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook